Roche Holding AG RHHVF OTC

Roche Holding AG (RHHVF) reported total assets of $100.75B and total liabilities of $62.85B for fiscal year 2025, resulting in total equity of $37.9B.

The company held $15.48B in cash and short-term investments. Total debt stood at $34.45B, with net debt of $28.87B. The Debt-to-Equity (D/E) ratio was 0.91 (moderate).

Current ratio is 1.38, suggesting adequate short-term liquidity. Interest coverage is 12.1x (strong).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (94/100) — Total assets $100.75B and equity $37.9B support the company's competitive scale
• VALUE (60/100) — Debt-to-Equity 0.91 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 67/100 with 4/7 criteria passed.

RHHBF

Roche Holding AG

$418.50

+1.82%

RHHBY

Roche Holding AG

$51.02

+0.65%

AZN

AstraZeneca PLC

$204.38

+1.06%

NVSEF

Novartis AG

$156.48

+0.00%

NVS

Novartis AG

$153.38

-0.71%

AZNCF

AstraZeneca PLC

$189.90

-1.35%

GSK

GSK plc

$59.18

+0.41%

BMY

Bristol-Myers Squibb Company

$58.08

+0.03%